Omega Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OMGA research report →
Range $7 – $11
Price Chart
About the company
Omega Therapeutics, Inc. functions as a biopharmaceutical firm in its development phase. Its innovative OMEGA Epigenomic Programming platform leverages epigenetics—nature's fundamental system for gene regulation and cell differentiation—to engineer therapeutic solutions.
- CEO
- Kaan Certel
- IPO
- 2021
- Employees
- 93
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on OMGA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.90M
- P/E
- -0.08
- PEG
- -0.00
- P/S
- 2.55
- P/B
- 0.13
- EV/EBITDA
- -0.73
- Div Yield
- 0.00%
- Gross Margin
- -2028.93%
- Op Margin
- -3240.50%
- Net Margin
- -3148.93%
- ROE
- -118.82%
- ROIC
- -51.99%
Latest fiscal year · YoY change
- Revenue
- $3.09M+49.3%
- Gross Profit
- $-62,775,000-1914.0%
- Op Income
- $-100,261,000
- Net Income
- $-97,428,000+5.1%
- EPS
- $-1.80+15.9%
- OCF Growth
- +7.1%
- FCF Growth
- +5.5%
- 52W High
- $4.44
- 52W Low
- $0.03
- 50D MA
- $0.47
- 200D MA
- $1.21
- Beta
- 1.64
- RSI (14)
- 29
- Avg Volume
- 9.59M
No earnings-call transcripts are available for OMGA yet.
- Free Float
- 39.3%
- Shares Outstanding
- 55.37M
- Float Shares
- 21.73M
of shares held by institutions
56 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 363.95K | ▼ 1.05M |
| Raymond James Financial Services Advisors, Inc. | 59.47K | ▲ 21.31K |
| Wade G W & Inc | 10.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 24, 25 | Varsalone Jeffrey T | other | 0 |
| Dec 3, 24 | Mehrotra Ravi | other | 50,000 |
| Dec 3, 24 | Mehrotra Ravi | other | 0 |
| Nov 22, 24 | Nelson Jennifer Ann | other | 110,000 |
| Nov 22, 24 | Nelson Jennifer Ann | other | 110,000 |
| Nov 15, 24 | Certel Kaan | other | 340,000 |
| Oct 2, 24 | Rosiello Robert L. | other | 50,000 |
| Oct 2, 24 | Rosiello Robert L. | other | 0 |
| Jun 20, 24 | Szela Mary T | other | 25,000 |
| Jun 20, 24 | Boehm Rainer J. | other | 25,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OMGA coverage
Recent articles, reports, and earnings notes.
No research on OMGA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OMGA report →Omega Pacific Commences Drill Program at Williams Property
newsfilecorp.com · Sep 15
Omega Pacific Williams Property Exploration Program Update
newsfilecorp.com · Sep 1
Omega Pacific Outlines 2026 Exploration Program at the Williams Property
newsfilecorp.com · Aug 13
Omega Pacific Closes First Tranche of Non-Brokered Private Placement
newsfilecorp.com · May 1
Omega Pacific Clarifies Size of Previously Announced Private Placement
newsfilecorp.com · Mar 11
Omega Pacific Announces Non-Brokered Private Placement
newsfilecorp.com · Mar 10
Omega Pacific Acquires 100% of Williams Property
newsfilecorp.com · Nov 24
Omega Pacific Closes Non-Brokered Private Placement
newsfilecorp.com · Oct 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.